Literature DB >> 26294111

Genetic, immune and vasoactive factors in the vascular dysfunction associated with hypertension in pregnancy.

Sajjadh M J Ali1, Raouf A Khalil1.   

Abstract

INTRODUCTION: Preeclampsia (PE) is a major complication of pregnancy that could lead to maternal and fetal morbidity and mortality. The pathophysiological mechanisms of PE are not completely understood, but recent research has begun to unravel some of the potential mechanisms. AREAS COVERED: Genetic polymorphisms and altered maternal immune response may cause impaired remodeling of the spiral arteries; a potential early defect in PE. Inadequate invasion of cytotrophoblasts into the decidua leads to reduced uteroplacental perfusion pressure (RUPP) and placental ischemia/hypoxia. Placental ischemia causes the release of biologically active factors such as anti-angiogenic factors, inflammatory cytokines, reactive oxygen species, hypoxia-inducible factors, and angiotensin II receptor autoantibodies. These vasoactive factors could cause systemic vascular endotheliosis and consequent increase in vascular resistance and blood pressure, glomerular endotheliosis causing proteinuria, cerebrovascular endotheliosis causing cerebral edema, seizures and visual disturbances, and hepatic endotheliosis, which may contribute to the manifestations of HELLP syndrome. PE-associated vascular endotheliosis causes a decrease in vasodilator mediators such as nitric oxide, prostacyclin and endothelium-derived hyperpolarizing factor, an increase in vasoconstrictors such as endothelin-1, angiotensin II and thromboxane A2, and enhanced mechanisms of vascular smooth muscle contraction such as intracellular Ca(2+), protein kinase C and Rho-kinase. Changes in matrix metalloproteinase activity and extracellular matrix cause vascular remodeling and further vasoconstriction. EXPERT OPINION: Some of the genetic, immune and vasoactive factors involved in vascular endotheliosis could be used as biomarkers for early detection, and as potential targets for prevention and treatment of PE.

Entities:  

Keywords:  blood pressure; endothelium; preeclampsia; pregnancy; vascular smooth muscle

Mesh:

Substances:

Year:  2015        PMID: 26294111      PMCID: PMC4640938          DOI: 10.1517/14728222.2015.1067684

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN: 1472-8222            Impact factor:   6.902


  106 in total

1.  Maternal ethnicity, paternal ethnicity, and parental ethnic discordance: predictors of preeclampsia.

Authors:  Aaron B Caughey; Naomi E Stotland; A Eugene Washington; Gabriel J Escobar
Journal:  Obstet Gynecol       Date:  2005-07       Impact factor: 7.661

2.  Fine mapping and SNP analysis of positional candidates at the preeclampsia susceptibility locus (PREG1) on chromosome 2.

Authors:  E Fitzpatrick; H H H Göring; H Liu; A Borg; S Forrest; D W Cooper; S P Brennecke; E K Moses
Journal:  Hum Biol       Date:  2004-12       Impact factor: 0.553

3.  Mesangial AT1/B2 receptor heterodimers contribute to angiotensin II hyperresponsiveness in experimental hypertension.

Authors:  Said AbdAlla; Ahmed Abdel-Baset; Heinz Lother; Adel el Massiery; Ursula Quitterer
Journal:  J Mol Neurosci       Date:  2005       Impact factor: 3.444

4.  Maternal autoantibodies from preeclamptic patients activate angiotensin receptors on human mesangial cells and induce interleukin-6 and plasminogen activator inhibitor-1 secretion.

Authors:  Sol M Bobst; Mary-Clare Day; Larry C Gilstrap; Yang Xia; Rodney E Kellems
Journal:  Am J Hypertens       Date:  2005-03       Impact factor: 2.689

5.  Hypertension produced by reductions in uterine perfusion in the pregnant rat: role of tumor necrosis factor-alpha.

Authors:  B Babbette D LaMarca; William A Bennett; Barbara T Alexander; Kathy Cockrell; Joey P Granger
Journal:  Hypertension       Date:  2005-09-06       Impact factor: 10.190

6.  Role of endothelin in mediating tumor necrosis factor-induced hypertension in pregnant rats.

Authors:  B Babbette D LaMarca; Kathy Cockrell; Elizabeth Sullivan; William Bennett; Joey P Granger
Journal:  Hypertension       Date:  2005-05-31       Impact factor: 10.190

7.  Circulating concentrations of sFlt1 (soluble fms-like tyrosine kinase 1) in fetal and maternal serum during pre-eclampsia.

Authors:  Anne Cathrine Staff; Kristin Braekke; Nina Kittelsen Harsem; Torstein Lyberg; Mette R Holthe
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2005-09-01       Impact factor: 2.435

8.  Increased phospholipase A2 and thromboxane but not prostacyclin production by placental trophoblast cells from normal and preeclamptic pregnancies cultured under hypoxia condition.

Authors:  Robin S Bowen; Yanping Zhang; Yang Gu; David F Lewis; Yuping Wang
Journal:  Placenta       Date:  2005-05       Impact factor: 3.481

9.  Altered global gene expression in first trimester placentas of women destined to develop preeclampsia.

Authors:  S A Founds; Y P Conley; J F Lyons-Weiler; A Jeyabalan; W Allen Hogge; K P Conrad
Journal:  Placenta       Date:  2008-11-21       Impact factor: 3.481

10.  STOX1 overexpression in choriocarcinoma cells mimics transcriptional alterations observed in preeclamptic placentas.

Authors:  Virginie Rigourd; Caroline Chauvet; Sonia T Chelbi; Régis Rebourcet; Françoise Mondon; Franck Letourneur; Thérèse-Marie Mignot; Sandrine Barbaux; Daniel Vaiman
Journal:  PLoS One       Date:  2008-12-11       Impact factor: 3.240

View more
  20 in total

Review 1.  Matrix Metalloproteinases, Vascular Remodeling, and Vascular Disease.

Authors:  Xi Wang; Raouf A Khalil
Journal:  Adv Pharmacol       Date:  2017-09-19

2.  Decreased homodimerization and increased TIMP-1 complexation of uteroplacental and uterine arterial matrix metalloproteinase-9 during hypertension-in-pregnancy.

Authors:  Juanjuan Chen; Zongli Ren; Minglin Zhu; Raouf A Khalil
Journal:  Biochem Pharmacol       Date:  2017-05-12       Impact factor: 5.858

Review 3.  Matrix Metalloproteinases in Normal Pregnancy and Preeclampsia.

Authors:  Juanjuan Chen; Raouf A Khalil
Journal:  Prog Mol Biol Transl Sci       Date:  2017-05-22       Impact factor: 3.622

4.  Increased vascular and uteroplacental matrix metalloproteinase-1 and -7 levels and collagen type I deposition in hypertension in pregnancy: role of TNF-α.

Authors:  Wei Li; Ning Cui; Marc Q Mazzuca; Karina M Mata; Raouf A Khalil
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-06-16       Impact factor: 4.733

Review 5.  Comparative risks and predictors of preeclamptic pregnancy in the Eastern, Western and developing world.

Authors:  Ning Zhang; Jing Tan; HaiFeng Yang; Raouf A Khalil
Journal:  Biochem Pharmacol       Date:  2020-09-25       Impact factor: 5.858

6.  Maternal choline supplementation during murine pregnancy modulates placental markers of inflammation, apoptosis and vascularization in a fetal sex-dependent manner.

Authors:  Sze Ting Cecilia Kwan; Julia H King; Jian Yan; Xinyin Jiang; Emily Wei; Vladislav G Fomin; Mark S Roberson; Marie A Caudill
Journal:  Placenta       Date:  2017-03-30       Impact factor: 3.481

7.  Estrogen-induced FOS-like 1 regulates matrix metalloproteinase expression and the motility of human endometrial and decidual stromal cells.

Authors:  Chao Chen; Congcong Li; Weichun Liu; Feng Guo; Xi Kou; Si Sun; Taiyang Ye; Shanji Li; Aimin Zhao
Journal:  J Biol Chem       Date:  2020-01-14       Impact factor: 5.157

8.  Placental growth factor reverses decreased vascular and uteroplacental MMP-2 and MMP-9 and increased MMP-1 and MMP-7 and collagen types I and IV in hypertensive pregnancy.

Authors:  Zongli Ren; Ning Cui; Minglin Zhu; Raouf A Khalil
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-03-23       Impact factor: 4.733

9.  Response Gene to Complement 32 Maintains Blood Pressure Homeostasis by Regulating α-Adrenergic Receptor Expression.

Authors:  Jun-Ming Tang; Ning Shi; Kun Dong; Scott A Brown; Amanda E Coleman; Matthew A Boegehold; Shi-You Chen
Journal:  Circ Res       Date:  2018-10-12       Impact factor: 17.367

10.  Mechanisms of Endothelial Dysfunction in Hypertensive Pregnancy and Preeclampsia.

Authors:  J S Possomato-Vieira; R A Khalil
Journal:  Adv Pharmacol       Date:  2016-06-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.